印度喀拉拉邦医护人员中新冠病毒疫苗突破性感染的基因组调查 - Suppr

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.

作者信息

Philomina J Beena, Jolly Bani, John Neethu, Bhoyar Rahul C, Majeed Nisha, Senthivel Vigneshwar, Cp Fairoz, Rophina Mercy, Vasudevan Bindhu, Imran Mohamed, Viswanathan Prasanth, Arvinden V R, Joseph Anoop, Divakar Mohit Kumar, Nair Priyanka R, Shamnath Afra, Kumar P Jayesh, Jain Abhinav, Geetha P, Bajaj Anjali, Mathew Samatha, Gupta Vishu, Agrawal Srashti Jyoti, Scaria Vinod, Sivasubbu Sridhar, Radhakrishnan Chandni

机构信息

Department of Microbiology, Government Medical College, Kozhikode, Kerala, India.

CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, New Delhi, India; Academy for Scientific and Innovative Research, Human Resource Development Centre Campus, Ghaziabad, Uttar Pradesh, India.

出版信息

J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.018. Epub 2021 May 25.

DOI:10.1016/j.jinf.2021.05.018

PMID:34044037

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8143909/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faaa/8143909/468f32cb8028/gr1_lrg.jpg

相似文献

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.印度喀拉拉邦医护人员中新冠病毒疫苗突破性感染的基因组调查

J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.018. Epub 2021 May 25.

SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.一名医护人员在先前感染后出现的新型冠状病毒2型疫苗突破性感染。

J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.10.008. Epub 2021 Oct 19.

Breakthrough infection with SARS-CoV-2 delta variant in old-age homes in a Southern District of Kerala, India.印度喀拉拉邦南部地区养老院中出现的 SARS-CoV-2 德尔塔变异株突破性感染。

Indian J Public Health. 2022 Nov;66(Supplement):S36-S40. doi: 10.4103/ijph.ijph_1084_22.

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.在先前感染过 SARS-CoV-2 的医护人员中，单次接种 ChAdOx1 nCoV-19 疫苗后的抗体反应。

EBioMedicine. 2021 Aug;70:103523. doi: 10.1016/j.ebiom.2021.103523. Epub 2021 Aug 12.

Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India.印度奥里萨邦疫苗突破性新冠病毒毒株的基因组概况。

Int J Infect Dis. 2022 Jun;119:111-113. doi: 10.1016/j.ijid.2022.03.042. Epub 2022 Mar 28.

Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers.接种疫苗的医护人员中突破性 SARS-CoV-2 感染的危险因素。

PLoS One. 2021 Oct 15;16(10):e0258820. doi: 10.1371/journal.pone.0258820. eCollection 2021.

Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia.医护人员对灭活的 SARS-CoV-2 疫苗的抗体反应，印度尼西亚。

Int J Infect Dis. 2021 Dec;113:15-17. doi: 10.1016/j.ijid.2021.09.078. Epub 2021 Oct 3.

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.加利福尼亚州旧金山湾区疫苗突破性病例中抗体耐药的 SARS-CoV-2 变异株占优势。

Nat Microbiol. 2022 Feb;7(2):277-288. doi: 10.1038/s41564-021-01041-4. Epub 2022 Jan 10.

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.信使 RNA 新冠病毒 2019 疾病（COVID-19）疫苗对医护人员队列中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性。

Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379. doi: 10.1093/cid/ciab361.

ChAdOx1 n-COV 19 Vaccine Protected Health Care Workers From Severe Infection Caused by the Variants.ChAdOx1 n-COV 19疫苗可保护医护人员免受变异毒株引起的严重感染。

Mayo Clin Proc. 2021 Oct;96(10):2726-2727. doi: 10.1016/j.mayocp.2021.07.016. Epub 2021 Aug 31.

引用本文的文献

Clinical characterization, molecular and genomic sequencing analysis of SARS-Cov-2 during second wave at Raigarh, Chhattisgarh, India.印度恰蒂斯加尔邦赖加德第二波新冠疫情期间新冠病毒的临床特征、分子及基因组测序分析

Bioinformation. 2024 Sep 30;20(9):1059-1064. doi: 10.6026/9732063002001059. eCollection 2024.

Severity of respiratory illness among Covid-19-vaccinated and non-vaccinated admitted patients-An observational study from a teaching hospital of Tripura.新冠肺炎疫苗接种者与未接种者中住院患者的呼吸道疾病严重程度——来自特里普拉一所教学医院的观察性研究

J Family Med Prim Care. 2024 May;13(5):2111-2115. doi: 10.4103/jfmpc.jfmpc_1643_23. Epub 2024 May 24.

Acceptance of Annual Booster Doses of COVID-19 Vaccines Among Indian Healthcare Professionals: A Pan-India Cross-Sectional Survey.印度医疗保健专业人员对新冠疫苗年度加强剂量的接受情况：一项全印度横断面调查。

Cureus. 2023 Nov 24;15(11):e49363. doi: 10.7759/cureus.49363. eCollection 2023 Nov.

Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases.突破性感染和未接种疫苗的 SARS-CoV-2 感染病例的死亡报告。

Disaster Med Public Health Prep. 2023 Mar 20;17:e359. doi: 10.1017/dmp.2023.4.

COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates.阿联酋接种疫苗人群中的 COVID-19 突破感染。

J Epidemiol Glob Health. 2023 Mar;13(1):67-90. doi: 10.1007/s44197-023-00090-8. Epub 2023 Feb 16.

Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients.在突破性感染患者中，从第二剂灭活疫苗到发病的时间间隔延长，抗 SARS-CoV-2 刺突免疫球蛋白 G 和免疫球蛋白 M 滴度下降。

Clin Respir J. 2023 Apr;17(4):270-276. doi: 10.1111/crj.13590. Epub 2023 Feb 9.

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India.印度浦那市第二波 COVID-19 期间的 SARS-CoV-2 突破感染。

Front Public Health. 2023 Jan 12;10:1040012. doi: 10.3389/fpubh.2022.1040012. eCollection 2022.

Epidemiological characteristics and quarantine assessment of imported international COVID-19 cases, March to December 2020, Chengdu, China.2020 年 3 月至 12 月期间，中国成都输入性新冠肺炎国际病例的流行病学特征和检疫评估。

Sci Rep. 2022 Dec 7;12(1):21132. doi: 10.1038/s41598-022-20712-8.

SARS-CoV-2 Variants of Concern and Variations within Their Genome Architecture: Does Nucleotide Distribution and Mutation Rate Alter the Functionality and Evolution of the Virus?关注的 SARS-CoV-2 变体及其基因组结构内的变异：核苷酸分布和突变率是否改变病毒的功能和进化？

Viruses. 2022 Nov 11;14(11):2499. doi: 10.3390/v14112499.

Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study.比较接种灭活疫苗和未接种灭活疫苗的 COVID-19 患者的病毒 RNA 脱落持续时间和抗 SARS-CoV-2 刺突 IgG 和 IgM 抗体滴度：一项回顾性研究。

BMC Infect Dis. 2022 Nov 9;22(1):831. doi: 10.1186/s12879-022-07808-2.

本文引用的文献

Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India.印度新德里一家慢性病医疗保健机构的医护人员和其他工作人员在接种疫苗后突破性感染 COVID19。

Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008. doi: 10.1016/j.dsx.2021.05.001. Epub 2021 May 3.

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白E484K突变降低抗体中和作用。

Lancet Microbe. 2021 Jul;2(7):e283-e284. doi: 10.1016/S2666-5247(21)00068-9. Epub 2021 Apr 7.

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.血清阴性和血清阳性医护人员接种一剂和两剂mRNA-1273后的反应原性、安全性及抗体反应。

J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.03.025. Epub 2021 Apr 1.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.腺病毒载体新冠疫苗（AZD1222）对 202012/01 关注变异株（B.1.1.7）的疗效：一项随机对照试验的探索性分析。

Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30.

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）501Y.V2变体的传染性并不更强，但确实存在免疫逃逸。

Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23.

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing.高通量检测和 SARS-CoV-2 的遗传流行病学研究：使用 COVIDSeq 下一代测序技术。

PLoS One. 2021 Feb 17;16(2):e0247115. doi: 10.1371/journal.pone.0247115. eCollection 2021.

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.鉴定导致 SARS-CoV-2 刺突突变的单克隆和血清抗体中和作用减弱的抗体。

Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4. doi: 10.1016/j.chom.2021.01.014. Epub 2021 Jan 27.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗（BBV152）的安全性和免疫原性：一项双盲、随机、1 期临床试验。

Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。

Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology.一种用于 SARS-CoV-2 谱系的动态命名建议，以辅助基因组流行病学研究。

Nat Microbiol. 2020 Nov;5(11):1403-1407. doi: 10.1038/s41564-020-0770-5. Epub 2020 Jul 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献